Frontiers in Oncology | Cancer Immunity and Immunotherapy

Original Research

Published on 21 Feb 2025

Prognostic significance of the inhibitory-to-stimulatory immune checkpoint ratio in patients with breast cancer

in Cancer Immunity and Immunotherapy

Chuangang Tang
Xiang Hu
Dawei Hao
Tao Chen
Pei Wang
Changwen Li
Chengling Chen
Yongcheng Li
Xiaowen Hao
Zeng Yuan

Frontiers in Oncology

doi 10.3389/fonc.2025.1524861

156 views

Case Report

Accepted on 19 Feb 2025

Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case report

in Cancer Immunity and Immunotherapy

Ilaria Gandolfini
Martina Manini
Giuseppe Daniele Benigno
Micaela Gentile
Alessandra Palmisano
Danio Somenzi
Letizia Gnetti
Marco Delsante
Benedetta Mordà
Marta D'angelo

Frontiers in Oncology

doi 10.3389/fonc.2025.1506324

Review

Accepted on 18 Feb 2025

Neoantigens: New Hope for Cancer Therapy

in Cancer Immunity and Immunotherapy

Yitong Hu
Zihao He
Ping Cai

Frontiers in Oncology

doi 10.3389/fonc.2025.1531592

Case Report

Accepted on 17 Feb 2025

Tislelizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer: a case report

in Cancer Immunity and Immunotherapy

Jie Zhu
Wen-jie Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1498701

Systematic Review

Published on 14 Feb 2025

Global research prospects and trends in TFH cells and tumors: a bibliometric analysis

in Cancer Immunity and Immunotherapy

Hao Lei
Jin Hu
Junpeng Zhu
Runze Li
Yu Zhao
Yaqi Zhao
Guisheng He
Tao Song
Chong Lu
Wuping Zheng

Frontiers in Oncology

doi 10.3389/fonc.2025.1443890

270 views

Review

Published on 14 Feb 2025

Are all programmed cell death protein 1 inhibitors the same?

in Cancer Immunity and Immunotherapy

Jochen H. Lorch
Stacey Stein
Martin J. Edelman

Frontiers in Oncology

doi 10.3389/fonc.2025.1535030

243 views

Original Research

Accepted on 13 Feb 2025

Circulating cell-free DNA methylation analysis of pancreatic cancer patients for early noninvasive diagnosis

in Cancer Immunity and Immunotherapy

Wenzhe Hu
Xudong Zhao
Nan Luo
Mengmeng Xiao
Feng Feng
Yuan An
Jianfei Chen
Long Rong
Yinmo Yang
Jirun Peng

Frontiers in Oncology

doi 10.3389/fonc.2025.1552426

Original Research

Accepted on 12 Feb 2025

Integrated single-cell analysis reveals the regulatory network of Disulfidptosis-related lncRNAs in bladder cancer: Constructing a prognostic model and predicting treatment response

in Cancer Immunity and Immunotherapy

Jiafu Xiao
Wuhao Liu
Jianxin Gong
Weifeng Lai
Neng Luo
Junrong Zou
Zhihua He

Frontiers in Oncology

doi 10.3389/fonc.2025.1527036

Case Report

Published on 12 Feb 2025

Case report: Low-dose radiation reverses pembrolizumab resistance in melanoma

in Cancer Immunity and Immunotherapy

Ka Hey Agnes Fong
Isaac Ho
Tsz Him So

Frontiers in Oncology

doi 10.3389/fonc.2025.1483117

342 views

Case Report

Accepted on 11 Feb 2025

Case report: metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor treated with chemotherapy and immune checkpoint inhibitor

in Cancer Immunity and Immunotherapy

Arthur Claessens
Jérome Plaza
Jean-Yves Blay

Frontiers in Oncology

doi 10.3389/fonc.2025.1549232

Original Research

Accepted on 11 Feb 2025

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma

in Cancer Immunity and Immunotherapy

Ruoyu Wang
Hongyu Pan
Minghao Ruan
Riming Jin
Jin Zhang
Yao Li
Dong Wu
Wen Sun

Frontiers in Oncology

doi 10.3389/fonc.2025.1385304

Review

Accepted on 11 Feb 2025

Research and progress of microRNA-136 in metastatic tumors Author Names

in Cancer Immunity and Immunotherapy

ZIxiong Chen
Chenwen Wang
Jang Wang
Wei Zhou

Frontiers in Oncology

doi 10.3389/fonc.2025.1555270

Review

Accepted on 10 Feb 2025

Advances in targeting protein S-palmitoylation in tumor immunity and therapy

in Cancer Immunity and Immunotherapy

Miaomiao Han
Lv Yuanhao
Yiyang Chen
Zhaoyi Li
Jiaqi Tian
Hongyan Zhou
Yunlong Wang
Wei Su
Jiateng Zhong

Frontiers in Oncology

doi 10.3389/fonc.2025.1547636

Case Report

Published on 07 Feb 2025

Dramatic response of advanced pulmonary sarcomatoid carcinoma to tislelizumab combined with anlotinib: a case report

in Cancer Immunity and Immunotherapy

Ranran Li
Xiliang Di
Yuan Li
Hao Li
Chonghua Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1531700

322 views

Original Research

Published on 07 Feb 2025

Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer

in Cancer Immunity and Immunotherapy

Yuanyuan Wang
Chenxi Hu
Tianpeng Du
Jiawen Li
Kaiyuan Hui
Xiaodong Jiang

Frontiers in Oncology

doi 10.3389/fonc.2025.1528004

192 views

Editorial

Published on 07 Feb 2025

Editorial: Deciphering the regulatory role of transcription factors in cancer immune infiltration

in Cancer Immunity and Immunotherapy

Qian Yang
Jinfen Xiao
Yujia Lan

Frontiers in Oncology

doi 10.3389/fonc.2025.1563949

232 views

Navigation group

Articles

Prognostic significance of the inhibitory-to-stimulatory immune checkpoint ratio in patients with breast cancer

Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case report

Neoantigens: New Hope for Cancer Therapy

Tislelizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer: a case report

Global research prospects and trends in TFH cells and tumors: a bibliometric analysis

Are all programmed cell death protein 1 inhibitors the same?

Circulating cell-free DNA methylation analysis of pancreatic cancer patients for early noninvasive diagnosis

Integrated single-cell analysis reveals the regulatory network of Disulfidptosis-related lncRNAs in bladder cancer: Constructing a prognostic model and predicting treatment response

Case report: Low-dose radiation reverses pembrolizumab resistance in melanoma

Case report: metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor treated with chemotherapy and immune checkpoint inhibitor

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma

Research and progress of microRNA-136 in metastatic tumors Author Names

Advances in targeting protein S-palmitoylation in tumor immunity and therapy

Dramatic response of advanced pulmonary sarcomatoid carcinoma to tislelizumab combined with anlotinib: a case report

Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer

Editorial: Deciphering the regulatory role of transcription factors in cancer immune infiltration